Abstract: The present invention provides novel Ruthenium-based transition metal complex catalysts comprising specific ligands, their preparation and their use in hydrogenation processes. Such complex catalysts are inexpensive, thermally robust, and olefin selective.

Abstract: Provided are a labelling agent including a compound of the following Formula 1, a labelling composition, a method of labelling a protein with the labelling agent, and a method of detecting the protein using the labelling agent: wherein R1, R2, R3, R4, R5, R6, and R8 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, R7 is H or —NR9R10, R9 and R10 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, X is —NR11, —O, or S, R11 is H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, Y is —OR12 or —NR13R14, R12 is H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, and R13 and R14 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl.

Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerization (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.

Abstract: The present invention refers to a process for the trans-selective hydroboration of internal alkynes and the so-obtained products. The inventive process makes use of a borane of the formula X1X2BH selected from the group of dialkyl boranes or di(alkoxy)boranes which are reacted with the internal alkynes in the presence of a cyclyopentadienyl-coordinated ruthenium catalyst.

Abstract: The present application relates to novel whitening agents for cellulosic substrates. The whitening agents are comprised of at least two constituents: at least one chromophore constituent and at least one polymeric constituent. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to light, or they may absorb light to reflect these same shades. This disclosure also relates to laundry care compositions including but not limited to liquid and/or powder laundry detergent formulations and rinse added fabric softening (RAFS) compositions that comprise such whitening agents.

Abstract: The invention relates to a ruthenium alkylidene complex comprising a 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand, the cycloalkyl group of said 1-aryl-3-cycloalkyl-imidazolin-2-ylidene ligand being a cyclic secondary aliphatic alkyl.

Abstract: A palladium(II) complex of formula (1) or a palladium(II) complex of formula (3). Also, processes for the preparation of the complexes, and their use in carbon-carbon and carbon-heteroatom coupling reactions.

Abstract: The present invention describes chemical systems and methods for silylating heteroaromatic organic substrates using at least alkoxide base, preferably a potassium alkoxide base and at least one organodisilane and (b) at least one alkoxide base. Both methods and compositions for affecting these transformations are disclosed.

Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Abstract: Compositions and methods comprising metal organic frameworks (MOFs) and related uses are generally provided. In some embodiments, an MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two unsaturated N-heterocyclic aromatic groups arranged about an organic core. In some embodiments, an MOF may be used in applications related to water adsorption.

Abstract: The invention relates to a universally applicable method for reducing the chlorine content of organomonophosphites using dimethylaminobutane or triethylamine.

Abstract: The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.

Abstract: Use of transition metal complexes of the formula (I) in organic light-emitting diodes where: M1 is a metal atom; carbene is a carbene ligand; L is a monoanionic or dianionic ligand; K is an uncharged monodentate or bidentate ligand selected from the group consisting of phosphines; CO; pyridines; nitriles and conjugated dienes which form a ? complex with M1; n is the number of carbene ligands and is at least 1; m is the number of ligands L, where m can be 0 or ?1; o is the number of ligands K, where o can be 0 or ?1; where the sum n+m+o is dependent on the oxidation state and coordination number of the metal atom and on the denticity of the ligands carbene, L and K and also on the charge on the ligands carbene and L, with the proviso that n is at least 1, and also an OLED comprising these transition metal complexes, a light-emitting layer comprising these transition metal complexes, OLEDs comprising this light-emitting layer, devices comprising an OLED according to the present invention, and specific tr

Abstract: Compounds of formula I and a process for manufacturing the compounds. A method of using the compounds for the detection of calcium ions and a method of detecting intracellular calcium are also described.

Abstract: The present invention provides stable, cyclic bent allene metal complexes and methods of conducting chemical processes, preferably olefin hydrogenation, comprising contacting an olefin substrate, preferably an unsaturated polymer, with a cyclic bent allene metal complex as described herein, under hydrogenation conditions.

Abstract: Benzothiazole phosphonate analogs and methods of using the same to inhibit the activity of Amyloid Binding Alcohol Dehydrogenase and in the amelioration or treatment of Alzheimer's disease are provided.

Abstract: The invention relates to the use of compounds of formulae (I) and/or (II) as colorless IR absorbers wherein M is Ni, Pd, Pt, Au, Ir, Fe, Zn, W, Cu, Mo, In, Mn, Co, Mg, V, Cr or Ti, X1, X2 and X3 are each independently of the others sulfur or oxygen, R1, R2, R3, R4, R5 and R6 are each independently of the others hydrogen, NR7R8, unsubstituted or substituted C1-C18alkyl, C1-C18 alkyl wherein the alkylene chain is interrupted with oxygen, unsubstituted or substituted C1-C18alkenyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, R7 and R8, each independently of the other, being unsubstituted or substituted C1-C18alkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, a further IR absorber optionally being added to the compounds of formulae (I) and (II).

Abstract: The present invention relates to the ferrocene derivative represented by formula (IA) or formula (IB), or to the pharmaceutically acceptable salt or solvate thereof and to the pharmaceutical composition thereof. Wherein, R is independently selected from H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy or C1-C6 alkoxy-C1-C6 alkoxy; Z is selected from O, S or NR1, wherein R1 is independently H or C1-C6 alkyl; n is an integer from 0 to 5. The present invention also provides a method and the pharmaceutical application thereof for preparing the compounds represented by formula (IA) or formula (IB) or the pharmaceutically acceptable salts thereof. The compounds have a strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT116 and/or breast cancer cell line MCF-7.

Abstract: Method of processing and handling solids and mixtures capable of deflagration, in particular of processing materials capable of deflagration in the chemical and pharmaceutical industry, wherein the processing and handling is carried out in an environment under a reduced pressure of ?500 mbara and the processing and/or handling comprises one or more process steps selected from the group consisting of filtration, milling, sieving, mixing, homogenization, granulation, compacting, packaging, drying, storage and transport in a transport container and other steps in apparatuses having mechanical internals.

Abstract: Various embodiments for a hand-held device to determine a level of one or more cannabinoid compounds in exhaled human breath are provided; some embodiments may also determine a level of alcohol in the exhaled breath. The device may perform any of the following steps: capture, concentrate, separate, identify, and quantify the level of cannabinoids in the exhaled human breath. The device may use solvent extraction and liquid chromatography to concentrate and separate cannabinoids from breath contaminants, followed by selective chemical modification of the cannabinoids with a fluorescent indicator for quantification. The measurement methodology may also include real time calibration of the device and detection protocol using known cannabinoid standards, which are simultaneously analyzed along with an unknown, to quantify the level of cannabinoids captured from the breath sample.